腺苷的心脏保护作用：“一个包裹在谜团中的谜题”。
Cardioprotection with adenosine: 'a riddle wrapped in a mystery'.
作者信息
Przyklenk Karin, Whittaker Peter
机构信息
Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA.
出版信息
Br J Pharmacol. 2005 Jul;145(6):699-700. doi: 10.1038/sj.bjp.0706261.
Abstract
Review of the published literature on adenosine and cardioprotection could lead one to paraphrase the famous words of Sir Winston Churchill (Radio broadcast, 1 October 1939 (in reference to Russia)) and conclude: 'I cannot forecast to you the action of adenosine. It is a riddle wrapped in a mystery inside an enigma'. That is, although it is well-established that adenosine can render cardiomyocytes resistant to lethal ischemia/reperfusion-induced injury, new and intriguing insights continue to emerge as to the mechanisms by which adenosine might limit myocardial infarct size.
摘要
回顾已发表的关于腺苷与心脏保护作用的文献，可能会让人套用温斯顿·丘吉尔爵士（1939年10月1日广播讲话（关于俄罗斯））的名言并得出结论：“我无法向你们预测腺苷的作用。它是一个包裹在谜团中的谜，谜中还有谜”。也就是说，尽管腺苷能够使心肌细胞对致死性缺血/再灌注诱导的损伤产生抗性这一点已得到充分证实，但关于腺苷限制心肌梗死面积的机制，仍不断有新的、引人入胜的见解出现。
相似文献
1
Cardioprotection with adenosine: 'a riddle wrapped in a mystery'.
Br J Pharmacol. 2005 Jul;145(6):699-700. doi: 10.1038/sj.bjp.0706261.
2
New insights into adenosine-mediated myocardial protection.
Br J Pharmacol. 2005 Jul;145(6):701-2. doi: 10.1038/sj.bjp.0706262.
3
Partial role of nitric oxide in infarct size limiting effect of quercetin and rutin against ischemia-reperfusion injury in normal and diabetic rats.
Indian J Exp Biol. 2011 Mar;49(3):207-10.
4
Intravenous adenosine protects the myocardium primarily by activation of a neurogenic pathway.
Br J Pharmacol. 2005 Jul;145(6):703-11. doi: 10.1038/sj.bjp.0706258.
5
Protective effect of ligustrazine against myocardial ischaemia reperfusion in rats: the role of endothelial nitric oxide synthase.
Clin Exp Pharmacol Physiol. 2012 Jan;39(1):20-7. doi: 10.1111/j.1440-1681.2011.05628.x.
6
Preconditioning with acute and chronic lithium administration reduces ischemia/reperfusion injury mediated by cyclooxygenase not nitric oxide synthase pathway in isolated rat heart.
Eur J Pharmacol. 2008 Nov 12;597(1-3):57-63. doi: 10.1016/j.ejphar.2008.08.010. Epub 2008 Aug 22.
7
[Cardioprotection of adenosine treatment in cadaver donor rats with warm ischemia].
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010 Aug;35(8):885-91. doi: 10.3969/j.issn.1672-7347.2010.08.019.
8
Adenosine-A1 receptors activation restores the suppressed cardioprotective effects of ischemic preconditioning in hyperhomocysteinemic rat hearts.
J Cardiovasc Pharmacol. 2009 Sep;54(3):204-12. doi: 10.1097/FJC.0b013e3181b04cc5.
9
Delayed 24 hours Nomega-nitro-L-arginine methyl ester injection induces pharmacological cardioprotection against reperfusion injury.
Cell Mol Biol (Noisy-le-grand). 2007 Jan 21;52 Suppl:OL868-73.
10
Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs.
Cardiovasc Res. 1996 May;31(5):711-8. doi: 10.1016/0008-6363(95)00235-9.
引用本文的文献
1
Repeated Remote Ischemic Conditioning Effect on Ankle-brachial Index in Diabetic Patients - A Randomized Control Trial.
Adv Biomed Res. 2017 Mar 7;6:28. doi: 10.4103/2277-9175.201685. eCollection 2017.
2
Cardiac purinergic signalling in health and disease.
Purinergic Signal. 2015 Mar;11(1):1-46. doi: 10.1007/s11302-014-9436-1. Epub 2014 Dec 20.
3
Remote ischemic preconditioning in patients with intermittent claudication.
Clinics (Sao Paulo). 2013 Apr;68(4):495-9. doi: 10.6061/clinics/2013(04)10.
4
Adenosine kinase: exploitation for therapeutic gain.
Pharmacol Rev. 2013 Apr 16;65(3):906-43. doi: 10.1124/pr.112.006361. Print 2013 Jul.
本文引用的文献
1
Intravenous adenosine protects the myocardium primarily by activation of a neurogenic pathway.
Br J Pharmacol. 2005 Jul;145(6):703-11. doi: 10.1038/sj.bjp.0706258.
2
Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes.
Cardiovasc Res. 2005 Mar 1;65(4):803-12. doi: 10.1016/j.cardiores.2004.12.004.
3
Preconditioning the myocardium: from cellular physiology to clinical cardiology.
Physiol Rev. 2003 Oct;83(4):1113-51. doi: 10.1152/physrev.00009.2003.
4
Cardioprotection 'outside the box'--the evolving paradigm of remote preconditioning.
Basic Res Cardiol. 2003 May;98(3):149-57. doi: 10.1007/s00395-003-0406-y.
5
Sites of action of adenosine in interorgan preconditioning of the heart.
Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H29-37. doi: 10.1152/ajpheart.01031.2001.
6
Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist AMP 579 administered at reperfusion.
J Mol Cell Cardiol. 2000 Dec;32(12):2339-47. doi: 10.1006/jmcc.2000.1264.
7
Comparison of interstitial fluid and coronary venous adenosine levels in in vivo porcine myocardium.
J Mol Cell Cardiol. 1998 Jun;30(6):1137-47. doi: 10.1006/jmcc.1998.0683.
8
Ischemic preconditioning: exploring the paradox.
Prog Cardiovasc Dis. 1998 May-Jun;40(6):517-47. doi: 10.1016/s0033-0620(98)80002-9.
9
Myocardial protection by brief ischemia in noncardiac tissue.
Circulation. 1996 Nov 1;94(9):2193-200. doi: 10.1161/01.cir.94.9.2193.
10
Intramyocardial injections and protection against myocardial ischemia. An attempt to examine the cardioprotective actions of adenosine.
Circulation. 1996 Jun 1;93(11):2043-57. doi: 10.1161/01.cir.93.11.2043.
Zotero 插件